论文部分内容阅读
目的观察硝苯地平联合厄贝沙坦治疗糖尿病合并高血压的临床疗效及安全性。方法选取2014年5月-2016年6月医院接收的2型糖尿病合并高血压患者78例,按照数字表法分成研究组40例和对照组38例。2组均给予常规控压基础治疗,对照组在此基础上口服硝苯地平控释片治疗,研究组在对照组基础上加用厄贝沙坦治疗,观察2组临床疗效,治疗前后血压、血糖、血肌酐、24h尿微量白蛋白及不良反应发生情况。结果研究组患者的总有效率为90.00%高于对照组的81.57%,差异有统计学意义(χ~2=5.497,P<0.05)。与治疗前对比,2组治疗后收缩压和舒张压均呈现明显的下降趋势,且研究组下降幅度优于对照组,差异均有统计学意义(P<0.05)。2组治疗前血肌酐、肾小球滤过率及24h尿蛋白定量比较差异无统计学意义(P>0.05),治疗后2组血肌酐、24h尿蛋白定量均低于治疗前,肾小球滤过率高于治疗前,且研究组治疗后优于对照组,差异均有统计学意义(P<0.05)。2组患者在治疗过程中均无严重不良反应发生,耐受性、依从性较好。结论硝苯地平联合厄贝沙坦治疗糖尿病合并高血压效果更好,能显著改善血压、血糖状况,且安全性好。
Objective To observe the clinical efficacy and safety of nifedipine combined with irbesartan in the treatment of diabetic hypertension. Methods From May 2014 to June 2016, 78 patients with type 2 diabetes mellitus complicated with hypertension received in the hospital were divided into 40 cases in the study group and 38 cases in the control group according to the digital table method. 2 groups were given conventional pressure-based treatment, the control group on the basis of oral nifedipine controlled release tablets, the study group in the control group based on the use of irbesartan treatment, observed two groups of clinical efficacy, blood pressure before and after treatment, Blood glucose, serum creatinine, 24h urinary albumin and adverse reactions occurred. Results The total effective rate of the study group was 90.00%, which was significantly higher than that of the control group (χ ~ 2 = 5.497, P <0.05). Compared with those before treatment, systolic and diastolic blood pressure showed a significant decreasing trend after treatment in both groups, and the decreasing rate in the study group was better than that in the control group (P <0.05). There were no significant differences in serum creatinine, glomerular filtration rate and 24-hour urinary protein before treatment between the two groups (P> 0.05). The serum creatinine and 24-hour urinary protein in 2 groups after treatment were lower than those before treatment The filtration rate was higher than before treatment, and the study group was better than the control group after treatment, the differences were statistically significant (P <0.05). Two groups of patients in the course of treatment were no serious adverse reactions, tolerance, compliance is better. Conclusion Nifedipine combined with irbesartan in the treatment of diabetes with hypertension better, can significantly improve blood pressure, blood glucose status, and good safety.